1. Home
  2. APA vs GKOS Comparison

APA vs GKOS Comparison

Compare APA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo APA Corporation

APA

APA Corporation

HOLD

Current Price

$42.38

Market Cap

12.3B

Sector

Energy

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$181.91

Market Cap

10.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APA
GKOS
Founded
1954
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
10.9B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
APA
GKOS
Price
$42.38
$181.91
Analyst Decision
Hold
Strong Buy
Analyst Count
23
12
Target Price
$31.96
$126.92
AVG Volume (30 Days)
5.8M
876.4K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
2.48%
N/A
EPS Growth
75.77
N/A
EPS
3.37
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
$3.86
$23.32
Revenue Next Year
N/A
$27.43
P/E Ratio
$12.22
N/A
Revenue Growth
N/A
32.33
52 Week Low
$21.64
$73.16
52 Week High
$45.66
$191.62

Technical Indicators

Market Signals
Indicator
APA
GKOS
Relative Strength Index (RSI) 61.50 60.38
Support Level $35.11 $175.04
Resistance Level $45.36 $184.00
Average True Range (ATR) 1.40 6.01
MACD -0.02 -1.59
Stochastic Oscillator 60.96 39.63

Price Performance

Historical Comparison
APA
GKOS

About APA APA Corporation

APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: